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The West Nile Virus (WNV)
Flaviviridae – Flavivirus - Japanese encephalitis serocomplex
Lineage 1 Lineage 2
 widespread 
 highly pathogenic, 
neuroinvasive
 Sub-Saharan Africa 
and Madagascar
 Europe
 neuroinvasive strains
Transmission cycle 
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Incidental hosts
The Virus
The Carrier
Amplifier, Reservoir, Distributor
WNV infections
 asymptomatic
 Hu: WNV fever
 Hu: 1% neurological disease, polioencephalomyelitis
Eq: 10%
Clinical manifestation:
strain
individual factors 
presence of antibodies against other ﬂaviviruses
Clinical signs
 non-specific signs
general depression
loss of appetite
low-grade fever
colic-like symptoms
lameness, stiffness
poor performance
Clinical signs
Clinical manifestation % of horses
Weakness (forelimb?) 78
Ataxia (forelimb?) 72
Muscle fasciculations 39
Recumbency 39
Hyperesthesia 28
Cranial nerve deficit 28
Asymmetric gait 22
Behavioural abnormality 17
Clinical signs
Clinical signs

Laboratory parameters
 Haematology: +/- increased white blood cell count 
& neutrophilia
 Metabolic profiles:
non diagnostic
 Cerebrospinal fluid: high protein +/- pleocytosis 
with lymphocytes or neutrophils
WNV outbreaks
 between August and November
 horses showing neurological symptomes
 diagnosis based on
 epidemiology
 clinical signs
 serology
 postmortem: histopathology, PCR, virus isolation
Serology
 IgM ELISA
 IgG ELISA
 PRNT
 extensive cross-reactive antibody response to other
Flaviviruses (molecular tests)
 urine?
Diagnostics
Differential Diagnosis
 Wobbler-syndrome (CVM)
 Trauma 
 Equine Herpesvirus Encephylomyelitis
 Rabies, Borna
 Parasitic migration
 Bacterial meningitis
 Degenerative myeloencephalopathia
 Botulism
 Tick-borne encephalitis
 Other myelo/encephalopathies
Colic Lamness
Nervous system
IgM Elisa positivity is not a diagnosis!
Scenario: 
 13 years old pony
 neurlogoc signs started in April
 progressive ataxia, dysphagia, pharyngeal, 
laryngeal paralysis
 IgM Elisa positive in July
 Vaccinated 2 years ago?
RESPE
Outcome
 30% died, 70% recovered, 30% residual CNS 
signs 
Serosurvey
Number of
premises
Tested Positive Showing 
clinical signs
Dead % of 
positive 
animals
% positive 
animals
showing
clinical
signs
Case-
fatality rate 
%
Affected
premises
15 105 47 18 5 44,7 38,3 27,8
Non-affected
premises 3 184 45 0 0 24,4 0 0
Total 18 289 92 18 5 31,8 19,5 27,8
Hungary
 both lineage 1 and 2 strains circulating
 clinical cases by linegae 2 strains
Case distribution
Av2004: avian WNVcases in 2004
Av2005: avian WNVcases in 2005
Ov2005: sheep encephalomyelitis
Av2007: avian WNVcases in 2007
Eq2007:first equine
encephyalomyelitis in 2007
Equine cases in 2008
Human cases in 2008 Avian cases (hawks) in 2008
Europe
2008-2012
Lineage 2 strain
Lineage 2 strain 
Lineage 1 strains
European Centre for Disease Prevention and 
Control
ECDC data
Human data 2014 AUG-OCT
country Number of cases
Austria 1
Greece 15
Hungary 11
Italy 24
Romania 23
Bosnia and Herzegovina 13
Russian Federation 29
Serbia 76
OIE reported 2008-2015

2015
Prevention
 Vaccination
 Education, information
 Need for persistent serosurvey and virus isolation
Postvaccination IgG, IgM
 Lineage 1 vaccines are protective
The West Nile Virus (WNV)
 zoonotic
 reportable to EU
 in Hungary: IgM ELISA only NFCSO central lab
 test paid by the state
 actions: report exact GPS coordinates, in case of a 
death PCR analysis 
Outbreaks
 non-predictable
 eg. 2012 USA, 286 human deaths in Texas
 Macedonia, Greece: 2010-2011
Thank you for your attention!
